AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic …

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ...

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with ...
Fierce Biotech

MoonLake’s phase 2 arthritis win kicks off pivotal year for IL-17 nanobody

MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a ...
Fierce Biotech

AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...
ascopubs.org

Randomized phase II study to evaluate treatment with induction therapy with nivolumab plus ipilimumab, followed by nivolumab with chemoradiotherapy versus standard of care with ...

TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of ...
ascopubs.org

A phase II study of ACR-368 and low dose gemcitabine combination therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck ...
Comicbook.com

Genshin Impact Banners Revealed for Version 5.6 Phase 2

The second phase of Genshin Impact Version 5.6 begins on May 27th, bringing a new set of banners. Ahead of the update, HoYoverse has revealed the full details for the new wishes that will arrive in ...